PharmaFocus Today – Page 376 – media

Vaccination, Paxlovid decrease risk of long Covid, studies show

People who are vaccinated or who take Paxlovid during a Covid-19 infection have a lower risk of developing long Covid, new research shows. The US Centers for Disease Control and Prevention defines long Covid as new, returning or ongoing health issues more than four weeks after an initial infection. According to the CDC, 1 in 5 Covid-19 survivors ages 18 to 64 and 1 in 4 survivors 65 or older have an ongoing health issue that might be attributable to Covid-19 infection。 A study published Thursday in JAMA Internal Medicine analyzed data from 41 studies, including more 860,000 people around the world. Of the four studies with vaccination information of nearly 250,000 people, those who had been vaccinated against Covid-19 had almost half the risk of long Covid than people who weren’t vaccinated. “These findings are important because they enable us to better understand who may develop ...
- Source: drugdu
- 127
- March 30, 2023
Royal Papworth Hospital robot for thoracic surgery to be UK first

A cutting-edge surgical robot is to be installed at the Royal Papworth Hospital in Cambridge. The Versius technology mimics human arm joints but has up to four times more rotation than the human wrist. It will be used in thoracic surgery, which includes heart and lungs, in a first for the UK. The device should make the surgery less invasive, improve outcomes and speed up patients’ recovery times, the hospital said. Staff at the hospital are to undergo a full training programme, with the first treatment due to start this spring. The technology is a partnership between the Royal Papworth and Cambridge-based company CMR Surgical. The robot is smaller than previous examples and is portable so it can be used in different theatres and for different specialities, which could include transplantation. “Our vision is to provide tomorrow’s treatment to today’s patients,” said Tim ...
- Source: drugdu
- 123
- March 30, 2023
International trade of colistin in animal feed continues unabated

In a recent study published in the journal The Lancet’s Microbe, researchers investigate Enterobacterales species resistance to colistin in Pakistan. Moreover, the researchers report on colistin import and export, use, and socioeconomic variables associated with colistin resistance. Background Studies have reported that colistin use in farming in China has driven Mcr-1-mediated resistance in Escherichia coli (MCRPEC), particularly in animal feed and prophylaxis. As a result, a ban on the agricultural use of colistin was enforced in April 2017, which reduced the prevalence of MCRPEC. However, colistin is used widely in food-producing animals in other nations for growth, prophylaxis, and treatment of colibacillosis. The spread of plasmid-mediated colistin resistance in Enterobacterales in the environment, among humans and food-producing animals has raised population health concerns. Even though colistin resistance decreased in China following its ban, colistin manufacture and export as pharmaceutical raw materials (PRMs) or feed additives continues. About the ...
- Source: drugdu
- 106
- March 30, 2023
prioritizing efficacy when considering quality of life

It is an exciting yet challenging time to be a treating physician in oncology, particularly in kidney cancer. The last decade of scientific innovation has brought an unprecedented shift in treatment options, and people now live longer than before with kidney cancer. Despite this, kidney cancers are the tenth most common cancer globally, with renal cell carcinoma (RCC) the most common type of kidney cancer, making up about 85% of diagnoses. There is no known cure for people living with advanced RCC, and the 5-year survival rate is around 12%, demonstrating the importance of continuing to find new innovative treatments. The introduction of next-generation tyrosine kinase inhibitors, immunotherapy-based agents, and, more recently, combination therapies have transformed the clinical outcomes of people living with RCC. However, with innovation comes more choice and increasingly complex therapeutic decision-making – often raising questions around the optimal sequence of treatments, particularly in more advanced ...
- Source: drugdu
- 229
- March 30, 2023
Alzheimer’s Association report highlights need to improve patient-physician communication Both individuals and primary care physicians reported a reluctance to address cognitive concerns

A new report from the Alzheimer’s Association has highlighted a need to improve patient-physician communication surrounding cognitive concerns. Following results from its 2023 Alzheimer’s Disease Facts and Figures report, the organisation said that a reluctance by the public and doctors to address memory and thinking worries hinders diagnosis and access to potential new treatments. “Providing the best possible care for Alzheimer’s disease requires conversations about memory at the earliest point of concern and a knowledgeable, accessible care team that includes physician specialists to diagnose, monitor disease progression and treat when appropriate,” said Maria Carrillo, chief science officer, Alzheimer’s Association. An accompanying report, The Patient Journey In an Era of New Treatments, also provides new insights from patients and primary care physicians (PCPs) on the current barriers to addressing cognitive concerns. Most focus group participants said their memory and thinking problems would need to have a significant ...
- Source: drugdu
- 142
- March 28, 2023
Chiesi Group and Affibody AB partner on respiratory disease treatments The companies will progress up to three programmes against undisclosed target

The Chiesi Group and Affibody AB have announced a collaboration and licensing agreement aimed at developing and commercialising innovative treatments for respiratory diseases. The partnership will see both companies utilise Affibody’s proprietary technology to progress up to three programmes against undisclosed targets for respiratory diseases. Italy-based biopharma Chiesi will fund all discovery, development and subsequent commercialisation worldwide alone, with Affibody retaining the option to co-promote in the Nordic region. The small size of Affibody’s molecules in combination with their robustness allows for the unique attributes explored under this collaboration, the companies explained, such as broad distribution and sustained exposure in the lung, as seen in preclinical models. David Bejker, chief executive officer of Affibody, said: “This collaboration with Chiesi accelerates Affibody’s strategic development and further reinforces the competitiveness of our technology which has now been validated both clinically and commercially. “We acknowledge and appreciate Chiesi’s ...
- Source: drugdu
- 131
- March 28, 2023
Complications, pathophysiology, and treatment of type 2 diabetes differ by sex

In a recent review published in the journal Diabetologia, researchers in Austria discussed the sex-based differences in the risk factors, diagnosis, and therapeutic approaches for type 2 diabetes and associated complications to improve awareness about and management options for all diabetes type 2 patients. Background Studies show that patterns associated with type 2 diabetes vary according to sex, with the prevalence of the disease being higher among the young to middle-aged male population but the increase in postprandial glucose levels being higher among women and increasing with age. Furthermore, the varying clinical outcomes based on sex depend on the influence of hormonal and genetic factors on the diagnoses, therapeutic response, clinical outcomes, and pathophysiology. Therefore, because of the varying levels of sex hormones, the risk of type 2 diabetes and other cardiometabolic diseases also varies significantly for women. Additionally, substantial sex-based differences in lifestyles, behaviors, and approaches ...
- Source: drugdu
- 150
- March 28, 2023
Link found between late eating and higher consumption of ultra-processed foods

Bonaccio M, Ruggiero E, Di Castelnuovo A, et al. Association between Late-Eating Pattern and Higher Consumption of Ultra-Processed Food among Italian Adults: Findings from the INHES Study. Nutrients, 2023, DOI: 10.3390/nu15061497, https://www.mdpi.com/2072-6643/15/6/1497 In a recent study published in the journal Nutrients, researchers in Italy examined the associations between meal timing and food processing. Unhealthy diets are risk factors for obesity and related disorders. As such, strategies to tackle obesity have been focused on food compositions, resulting in recommendations to lower sugar, salt, and fat intake, with a concomitant increase in fiber, vitamin, and mineral intake. Much research has been centered on meal timing, with population studies implicating late eating in obesity and nutrition-related non-communicable diseases. Nonetheless, no study has investigated the relationship between meal timing and processed foods. About the study In the present study, researchers evaluated whether meal timing is associated with foods with different ...
- Source: drugdu
- 130
- March 28, 2023
Patients losing out amid slump in NHS clinical trials, warn top clinicians UK falls from fourth to 10th place in phase III trials amid ‘ossified’ bureaucracy and stretched health service

The state of clinical trials in the NHS is “much worse than it has been in years” with patients losing access to cutting-edge cancer and dementia treatments, one of the UK’s most senior clinicians has warned. Sir John Bell, the regius professor of medicine at the University of Oxford and a government life sciences adviser, said the UK’s approach needed “a full overhaul, top to bottom” to prevent a collapse in the number of clinical trials being conducted in the NHS. “I don’t think there’s any doubt that companies are choosing not to evaluate their drugs in the UK,” he said. “The risks [to patients] are much bigger than have been alluded to.” The intervention comes after the government launched an independent review led by the former health minister James O’Shaughnessy into why the NHS had seen a 44% drop in participants recruited to commercial clinical trials in the past five years. The UK is rapidly ...
- Source: drugdu
- 125
- March 28, 2023
GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate There are currently no licensed vaccines offering simultaneous protection against all five serogroups

GSK has reported positive top-line results from a phase 3 study of its five-in-one meningococcal vaccine candidate, MenABCWY, in healthy individuals aged ten to 25 years. Invasive meningococcal disease (IMD) is an uncommon but serious illness that can cause life-threatening complications or even death, with the highest incidence occurring in children and adolescents. Five Neisseria meningitides serogroups – A, B, C, W, and Y – account for nearly all IMD cases, but there are currently no licensed vaccines that offer simultaneous protection against all of them. In the US, two separate vaccines needing four injections are required to protect against all five serogroups. This regimen, together with low awareness of the disease, can lead to poor immunisation rates, with an estimated coverage of only 31% of adolescents in the US. It is hoped that GSK’s MenABCWY, which combines the antigenic components of its licensed Bexsero (MenB) and Menveo (MenACWY) meningococcal ...
- Source: drugdu
- 149
- March 27, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.